Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 12/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19505418 | 0.89 | PDE5A (0.42) | PDE5AADORA3P2RX3MEN1KMT2A | |
| SCHEMBL21499644 | 0.83 | PDE5A (0.40) | PDE5AP2RX3TSHR | |
| SCHEMBL21499684 | 0.80 | P2RX3 (0.44) | PDE5AP2RX3 | |
| SCHEMBL19505412 | 0.80 | TRPC4 (0.41) | PDE5AP2RX3TSHR | |
| SCHEMBL19505352 | 0.76 | PDE5A (0.33) | PDE5A | |
| SCHEMBL21499639 | 0.76 | PDE5A (0.39) | PDE5AADORA3P2RX3MEN1KMT2A | |
| SCHEMBL19505233 | 0.76 | P2RX3 (0.45) | PDE5AP2RX3 | |
| SCHEMBL19505499 | 0.76 | PDE5A (0.31) | PDE5A | |
| SCHEMBL19374881 | 0.76 | P2RX3 (0.44) | PDE5AP2RX3 | |
| SCHEMBL18834232 | 0.74 | P2RX3 (0.43) | PDE5AP2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230040259-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, LLC (US) | 2023-02-09 | — | — | US | disclosed |
| US-11208409-B2 | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES, LLC (US) | 2021-12-28 | — | — | US | disclosed |
| US-20190322667-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230040259-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | PDE5A 461/4885ADORA3 449/4885P2RX3 30/4885 |
| US-11208409-B2 | Substituted xanthines and methods of use thereof | TRPC5, TRPC7, TRPC4 | PDE5A 461/4885ADORA3 449/4885P2RX3 30/4885 |
| US-20190322667-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | PDE5A 461/4885ADORA3 449/4885P2RX3 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.